James B. Williams
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James B. Williams.
Veterinary Research Communications | 1985
Pak-Kan Albert Lo; David W. Fink; James B. Williams; J. Blodinger
Studies are reported which describe the effects of formulation, animal species, and route of administration on the pharmacokinetics of ivermectin. Biological half-life t1/2 increases in the order: swine (0.5 day) > dogs (1.8 day) > cattle ≌ sheep (2.8 day). Formulation modifications, based upon the solubility properties of the drug, have been directed towards the development of a nonaqueous injectable formulation for cattle and an aqueous vehicle for horses. Bioavailability following subcutaneous injection in cattle can be regulated by control of injection solvent composition: a vehicle composed of a mixed aqueous-organic solvent exhibits pharmacokinetic properties (i.e., Cp, t1/2, AUC, and F) intermediate between those furnished by an aqueous formulation and via a purely nonaqueous solvent. The longer apparent biological half-life from this latter vehicle (t1/2=8.3 days) confirms that a slow absorption process dominates the pharmacokinetics in the nonaqueous injectable product to produce an effective controlled-release formulation. These bioavailability results illustrate the increase in the concentration of an organic solvent and a concomitant decrease in surfactant concentration in a micellar aqueous system for prolonged drug delivery via injection.
Archive | 1981
Pak-Kan Albert Lo; James B. Williams
Archive | 1998
James B. Williams; Rey T. Chern
Archive | 1995
Kaushik J. Dave; James B. Williams
Archive | 1992
Elinor H Chen; James B. Williams
Archive | 1984
James B. Williams; Russell U. Nesbitt
Archive | 1996
Kaushik J. Dave; James B. Williams
Archive | 1994
Hoo-Kyun Choi; James B. Williams
Archive | 1994
Hoo-Kyun Choi; James B. Williams
Archive | 1986
James B. Williams; Russell U. Nesbitt